Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.48 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.37 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.36 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.52 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16968565 | 1.00 | PSIP1 (0.52) | PSIP1GAARORCLOXL2JAK2 | |
| SCHEMBL16441819 | 0.98 | PSIP1 (0.53) | PSIP1GAARORCLOXL2JAK2 | |
| SCHEMBL17168926 | 0.86 | LOXL2 (0.46) | PSIP1GAARORCLOXL2MAPT | |
| Hydrochloric Acid SCHEMBL560818 | 0.84 | LOXL2 (0.49) | PSIP1LOXL2MAPTKCNH2HTR2A | |
| SCHEMBL16977436 | 0.83 | GAA (0.44) | PSIP1GAARORCJAK2MAPT | |
| SCHEMBL15531386 | 0.82 | NAMPT (0.53) | PSIP1LOXL2KCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23145140 | 0.81 | CA2 (0.52) | MAPTKCNH2KDM4ETDP1HTR2A | |
| SCHEMBL568140 | 0.81 | LOXL2 (0.47) | PSIP1LOXL2KCNH2KDM4EHTR2A | |
| Hydrochloric Acid SCHEMBL29744315 | 0.81 | CA2 (0.52) | MAPTKCNH2KDM4ETDP1HTR2A | |
| SCHEMBL21299551 | 0.81 | PSIP1 (0.38) | PSIP1GAALOXL2MAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302185-B | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117800904-A | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113166061-B | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-112601745-B | Azaaryl amide derivative and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110392688-B | Compounds for inhibition of ROR-gamma-T | 伊莱利利公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-110337440-B | Compounds useful for inhibition of ROR-gamma-t | 伊莱利利公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021139599-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589637-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-9868748-B2 | Thiazolopyrrolidine inhibitors of ROR- γ | VITAE PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845308-B2 | Isoindoline inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9598431-B1 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044410-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| EP-2991994-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014179564-A1 | THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | GAA 1078/4885JAK2 380/4885KCNH2 2797/4885 |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | GAA 1185/4885JAK2 675/4885KCNH2 4371/4885 |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | GAA 1756/4885JAK2 549/4885KCNH2 3721/4885 |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | GAA 504/4885JAK2 64/4885KCNH2 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.